Related Experiment Video

Updated: May 29, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

The platelet-derived growth factor system in renal disease: an emerging role of endogenous inhibitors

Claudia R C van Roeyen1, Tammo Ostendorf, Jürgen Floege

  • 1Department of Nephrology and Clinical Immunology, RWTH University Hospital Aachen, Pauwelsstr. 30, D-52057 Aachen, Germany. cvanroeyen@ukaachen.de

European Journal of Cell Biology
|August 30, 2011
PubMed

Insights

Platelet-derived growth factor (PDGF) plays key roles in kidney diseases. Understanding its natural inhibitors, like NOV (CCN3), is crucial for developing new therapies targeting PDGF-mediated conditions.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Signaling

Background:

  • The platelet-derived growth factor (PDGF) system, comprising isoforms and receptors, is integral to renal cell functions.
  • PDGF signaling regulates cell proliferation, migration, extracellular matrix accumulation, and inflammation in the kidneys.
  • Dysregulated PDGF activity is implicated in mesangioproliferative glomerulonephritis, renal fibrosis, and angiogenesis.

Purpose of the Study:

  • To review the roles of PDGF isoforms and their receptors in renal physiology and pathology.
  • To explore the mechanisms and significance of endogenous PDGF inhibitors.
  • To highlight the potential of understanding these inhibitors for therapeutic development in PDGF-mediated kidney diseases.

Main Methods:

  • Literature review of studies on PDGF isoforms, receptors, and inhibitors in renal contexts.
  • Analysis of the biological functions of PDGF in kidney cells.
  • Examination of the regulatory mechanisms of endogenous PDGF inhibitors, including NOV (CCN3).

Main Results:

  • PDGF isoforms and receptors are expressed in renal cells, influencing key processes like proliferation and fibrosis.
  • Various endogenous inhibitors modulate PDGF activity at different levels of the signaling pathway.
  • The novel inhibitor nephroblastoma overexpressed gene (NOV, CCN3) inhibits PDGF-induced proliferation and is itself regulated by PDGF.

Conclusions:

  • A comprehensive understanding of PDGF system components and their endogenous inhibitors is vital for renal health.
  • NOV (CCN3) represents a significant endogenous inhibitor with potential therapeutic implications.
  • Further research into PDGF antagonists may pave the way for novel treatments for kidney diseases driven by PDGF signaling.

More Related Videos

Intravascular Delivery of Biologics to the Rat Kidney07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.